Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer

NCT05634499 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05634499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05634499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
June 27, 2023
Completion date
August 25, 2026
Enrollment
33 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer